给他们看钱：多方利益相关者对改革临床试验参与者报酬的看法。

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nature Reviews. Drug Discovery Pub Date : 2024-07-18 DOI:10.1038/d41573-024-00107-2

Gunnar Esiason, Angela Pontius, Luke Gelinas

{"title":"给他们看钱：多方利益相关者对改革临床试验参与者报酬的看法。","authors":"Gunnar Esiason, \n Angela Pontius, \n Luke Gelinas","doi":"10.1038/d41573-024-00107-2","DOIUrl":null,"url":null,"abstract":"Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem. Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 12","pages":"881-882"},"PeriodicalIF":122.7000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Show them the money: a multi-stakeholder perspective on reforming clinical trial participant compensation\",\"authors\":\"Gunnar Esiason, \\n Angela Pontius, \\n Luke Gelinas\",\"doi\":\"10.1038/d41573-024-00107-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem. Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem.\",\"PeriodicalId\":19068,\"journal\":{\"name\":\"Nature Reviews. Drug Discovery\",\"volume\":\"23 12\",\"pages\":\"881-882\"},\"PeriodicalIF\":122.7000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews. Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-024-00107-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00107-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

临床试验参与者的补偿早该进行深思熟虑的改革了。第一步：在组成研究生态系统的各利益相关方（包括患者）之间达成共识。临床试验参与者的报酬亟待深思熟虑的改革。第一步：让组成研究生态系统的各利益相关方（包括患者）达成共识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Show them the money: a multi-stakeholder perspective on reforming clinical trial participant compensation

Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem. Clinical trial participant compensation is badly overdue for thoughtful reform. The first step: generating consensus across the various stakeholders, including patients, who make up the research ecosystem.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.

期刊最新文献

NaV1.8 inhibitor poised to provide opioid-free pain relief Upcoming FDA approval decisions in Q1 2025 Top product forecasts for 2025 Can non-canonical amino acids open up non-canonical drug discovery opportunities? Showing tau the exit